***Background.*** We compared antibody responses to influenza vaccine in adults ≥50 years old in two consecutive seasons. In 2011-12, all participants received trivalent inactivated influenza vaccine (IIV3). In 2012-13, those age 50-64 received intradermal (ID) and those age ≥65 received high-dose vaccine (HD). In 2012-13, the WHO-recommended vaccine strains were modified for H3N2 and B.

***Methods.*** Participants were recruited in 2011 and vaccinated in the fall of 2011 and 2012. In both years, pre- and post (21-28 days)-vaccination sera were tested for antibody response to vaccine \[measured by hemagglutination inhibition (HI) titer\]. We compared geometric mean titers (GMT) and titer fold rise from pre- to post-vaccination in 2012, among 2011-12 responders (≥4-fold rise in HI titer from pre-to post-vaccination) and 2011-12 non-responders (\<4-fold rise in HI titer) to the corresponding vaccine strain.

***Results.*** 183 adults received IIV3 in 2011 and either HD (N = 82) or ID (N = 101) in 2012. For the 2011-12 vaccine, 56 (31%) responded to the H1N1 strain, 68 (37%) responded to H3N2, and 28 (15%) responded to B. Among HD recipients, post-vaccination GMT for H3N2 was higher among 2011-12 responders vs non-responders (p = 0.04). Fold rise did not differ significantly for any vaccine strains between responders vs non-responders.

                                      HD recipients     ID recipients                    
  ------ ---------------------------- ----------------- ---------------- --------------- ---------------
  H1N1   Post-vaccination GMT (IQR)   93 (57, 160)      128 (80, 320)    78 (40, 226)    105 (40, 160)
         Median fold rise (IQR)       4 (2, 8)          4 (1, 8)         2 (1, 4)        2 (2, 4)
                                                                                         
  H3N2   Post-vaccination GMT (IQR)   154 (80, 320)\*   242 (160, 452)   120 (57, 320)   118 (40, 226)
         Median fold rise (IQR)       4 (2, 8)          4 (2, 11)        2 (1, 4)        2 (1, 8)
                                                                                         
  B      Post-vaccination GMT (IQR)   185 (80, 320)     180 (80, 320)    137 (80, 320)   163 (80, 320)
         Median fold rise (IQR)       3 (1, 8)          2 (2, 11)        2 (1, 6)        3 (1, 16)

\* p \< 0.05 for comparison of 2011-12 responders and non-responders.

***Conclusion.*** Prior response to 2011-12 vaccine antigen was not associated with response to the new H3N2 or B antigens in 2012-13, nor was it associated with response to the H1N1 antigen used in both the 2011-12 and 2012-13 vaccines.
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